Damoun Safarpour1, Shabnam Pakneshan2, Fattaneh A Tavassoli1. 1. Department of Pathology, Yale University School of Medicine New Haven, CT, USA. 2. Department of Ophthalmology and Visual Sciences, Yale University School of Medicine New Haven, CT, USA.
Abstract
BACKGROUND: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in a subset of these tumors that are androgen receptor (AR) positive with potential benefit from anti-androgen therapy. Against this background, the frequency of AR expression alone and in combination with other markers and morphologic features was assessed to identify TNBC subtypes for targeted therapy. METHODS: 400 consecutive invasive mammary carcinomas with known estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2 status were selected for study. The frequency of AR positivity alone or in combination with other markers was recorded with specific attention to the morphology of AR+ TNBCs. Ki67 was evaluated in selected group of cases. ASCO/CAP guidelines were used for interpretation of the various biomarkers. RESULTS: Of the 400 tumors, 32 (8%) carcinomas were quadruple negative (ER-, PR-, AR-, Her2-), while 50 tumors (12.5%) were triple negative (ER-, PR-, Her2-); 18 (36%) of the triple negative tumors were AR positive and 10 (55%) of these were classic apocrine carcinomas. Fourteen cases, all apocrine carcinomas, were AR and Her2 positive. All 32 QN carcinomas were poorly differentiated and they had the highest Ki67 labeling index. CONCLUSION: The relatively high proportion of AR+ tumors (36%) among the 50 triple negative carcinomas is an important finding in support of routine assessment of AR in at least all TNBCs and apocrine carcinomas as a potential target for therapy.
BACKGROUND: Triple negative breast carcinomas (TNBC) do not benefit from hormonal or Herceptin therapies. In search of novel therapeutic targets for TNBC, interest is escalating in a subset of these tumors that are androgen receptor (AR) positive with potential benefit from anti-androgen therapy. Against this background, the frequency of AR expression alone and in combination with other markers and morphologic features was assessed to identify TNBC subtypes for targeted therapy. METHODS: 400 consecutive invasive mammary carcinomas with known estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR) and HER2 status were selected for study. The frequency of AR positivity alone or in combination with other markers was recorded with specific attention to the morphology of AR+ TNBCs. Ki67 was evaluated in selected group of cases. ASCO/CAP guidelines were used for interpretation of the various biomarkers. RESULTS: Of the 400 tumors, 32 (8%) carcinomas were quadruple negative (ER-, PR-, AR-, Her2-), while 50 tumors (12.5%) were triple negative (ER-, PR-, Her2-); 18 (36%) of the triple negative tumors were AR positive and 10 (55%) of these were classic apocrine carcinomas. Fourteen cases, all apocrine carcinomas, were AR and Her2 positive. All 32 QN carcinomas were poorly differentiated and they had the highest Ki67 labeling index. CONCLUSION: The relatively high proportion of AR+ tumors (36%) among the 50 triple negative carcinomas is an important finding in support of routine assessment of AR in at least all TNBCs and apocrine carcinomas as a potential target for therapy.
Authors: Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol Journal: J Clin Invest Date: 2011-07 Impact factor: 14.808
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Amelia A Peters; Grant Buchanan; Carmela Ricciardelli; Tina Bianco-Miotto; Margaret M Centenera; Jonathan M Harris; Shalini Jindal; Davendra Segara; Li Jia; Nicole L Moore; Susan M Henshall; Stephen N Birrell; Gerhard A Coetzee; Robert L Sutherland; Lisa M Butler; Wayne D Tilley Journal: Cancer Res Date: 2009-07-28 Impact factor: 12.701
Authors: Giuseppe Viale; Nicole Rotmensz; Patrick Maisonneuve; Luca Bottiglieri; Emilia Montagna; Alberto Luini; Paolo Veronesi; Mattia Intra; Rosalba Torrisi; Anna Cardillo; Elisabetta Campagnoli; Aron Goldhirsch; Marco Colleoni Journal: Breast Cancer Res Treat Date: 2008-10-07 Impact factor: 4.872
Authors: Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir Journal: J Natl Cancer Inst Date: 2013-11-22 Impact factor: 13.506
Authors: Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina Journal: Endocr Relat Cancer Date: 2015-02-26 Impact factor: 5.678
Authors: Akshay Anand; Kul R Singh; Surender Kumar; Nuzhat Husain; Jitendra K Kushwaha; Abhinav A Sonkar Journal: Breast Care (Basel) Date: 2017-06-16 Impact factor: 2.860
Authors: Valerie N Barton; Jessica L Christenson; Michael A Gordon; Lisa I Greene; Thomas J Rogers; Kiel Butterfield; Beatrice Babbs; Nicole S Spoelstra; Nicholas C D'Amato; Anthony Elias; Jennifer K Richer Journal: Cancer Res Date: 2017-05-16 Impact factor: 12.701
Authors: Tiffany A Traina; Kathy Miller; Denise A Yardley; Janice Eakle; Lee S Schwartzberg; Joyce O'Shaughnessy; William Gradishar; Peter Schmid; Eric Winer; Catherine Kelly; Rita Nanda; Ayca Gucalp; Ahmad Awada; Laura Garcia-Estevez; Maureen E Trudeau; Joyce Steinberg; Hirdesh Uppal; Iulia Cristina Tudor; Amy Peterson; Javier Cortes Journal: J Clin Oncol Date: 2018-01-26 Impact factor: 44.544